PROGRAM DEVELOPMENT GRANT ON BREAST CANCER

乳腺癌是美国女性中最常见的癌症。 据估计，1993年有175,000个新病例发生。目前， 每九个美国女性中就有一个会在有生之年患上乳腺癌。 在过去的几年里，乳腺癌的发病率每年增加2-3%。 绝经前和绝经后妇女的过去十年。乳腺癌 是导致女性癌症死亡的第二大原因，大约 预计1993年有45000人死于乳腺癌。整合 基础科学研究与临床研究的结合在 解决乳腺癌病因学和治疗方面的关键问题。 乳腺癌P20项目发展资助侧重于分子 乳腺癌病因学和治疗的目标，将涉及两个中心 在俄亥俄州立大学。俄亥俄州立大学综合癌症中心 (OSUCCC)和中心的亚瑟·G·詹姆斯癌症医院和研究 研究所(CHRI)为多学科提供重要机遇 乳腺癌的实验室和临床研究互动。《中心》 俄亥俄州立大学分子环境健康(CMEH) 重点研究分子毒理学、分子流行病学和 分子病理学。此外，一批关键的教职员工和研究人员 OSUCCC、CMEH和相关的医学、药学学院， 兽医和生物科学致力于乳腺癌 乳腺癌翻译研究的研究和发展。 这项P20项目开发资助的核心研究人员 乳腺癌涉及几个OSUCCC基础科学(激素和 癌症、癌变、治疗、基因表达)与临床 课程(外科肿瘤学、血液学/肿瘤学)。在以下方面的研究优势 内分泌学、发育治疗学、基因表达和 癌症的发生为整合这项研究提供了独特的机会 进入专注于乳房翻译研究目标的新项目 癌症病因学和治疗。 P20计划发展助学金的总体主题是解决分子 乳腺癌病因学和治疗的靶点。研究项目中心 围绕着小分子(类固醇、天然产物、 合成剂、环保剂)和大分子(多肽和 蛋白质激动剂/拮抗剂、抗体)具有关键的生物分子 乳腺癌的靶点(酶、受体、DNA)。研究项目和 该提案的发展规划有几个重要的方面 多学科聚焦于乳腺癌病因学和 心理治疗。项目的翻译研究目标主要集中在 将这些领域的基础科学整合和转化为临床 在P20提案的四年期间进行实践。主要组成部分 本P20计划发展补助金包括(1)计划说明 领导人，(2)对参与调查人员的讨论，他们的研究 计划的活动和发展，(3)发展计划 在环境因素方面强调新的跨学科项目 乳腺癌和乳腺癌新疗法的开发，(4)预算， (五)证明文件。

Mammary adenocarcinoma is the most common cancer among women in the United States, with an estimated 175,000 new cases occurring in 1993. Currently, one out of nine American women will develop breast cancer in her lifetime. The rate of breast cancer incidence has increased 2-3% per year over the past decade in both premenopausal and postmenopausal women. Breast cancer is the second major cause of cancer deaths in women, and approximately 45,000 deaths from breast cancer are anticipated in 1993. The integration of basic science research with clinical investigations is critical in addressing key issues in breast cancer etiology and therapy. The P20 Program Development Grant on Breast Cancer focuses on molecular targets In breast cancer etiology and therapy and will involve two centers here at The Ohio State University. The OSU Comprehensive Cancer Center (OSUCCC) and the Center's Arthur G. James Cancer Hospital and Research Institute (CHRI) provide important opportunities for multidisciplinary laboratory and clinical research interactions in breast cancer. The Center for Molecular Environmental Health (CMEH) at The Ohio State University emphasizes research in molecular toxicology, molecular epidemiology, and molecular pathology. Furthermore, a core of key faculty and researchers in the OSUCCC, the CMEH, and associated Colleges of Medicine, Pharmacy, Veterinary Medicine, and Biological Sciences are committed to breast cancer research and the development of translational studies in breast cancer. The nucleus of investigators of this P20 Program Development Grant on Breast Cancer are involved in several OSUCCC Basic Sciences (Hormones and Cancer, Carcinogenesis, Therapeutics, Gene Expression) and Clinical Programs (Surgical Oncology, Hematology/Oncology). Research strengths in areas of endocrinology, developmental therapeutics, gene expression, and carcinogenesis permit unique opportunities for integration of this research into new programs focusing on translational research objectives in breast cancer etiology and therapy. The overall theme of the P20 Program Development Grant addresses molecular targets In breast cancer etiology and therapy. The research projects center around the interactions of small molecules (steroids, natural products, synthetic agents, environmental agents) and large molecules (peptide and protein agonists/antagonists, antibodies) with critical biomolecular targets in breast cancer (enzymes, receptors, DNA). Research projects and developmental programs of the proposal have several important multidisciplinary focuses in the areas of breast cancer etiology and therapy. Translational research objectives of the projects focus on integration and transfer of the basic sciences in these areas into clinical practice in the four year period of the P20 proposal. The major components of this P20 Program Development Grant are (1) description of the program leaders, (2) discussions on the investigators involved, their research activities, and developments of the program, (3) the development plan emphasizing new interdisciplinary projects in environmental factors in breast cancer and development of new breast cancer therapies, (4) budgets, and (5) supporting documents.